T. Rowe Price Associates
JBIO

T. Rowe Price Associates’s Jade Biosciences JBIO Stock Holding History

T. Rowe Price Associates’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$318K Sell
22,578
-2,591
-10% -$37.5K ﹤0.01% 2659
2025
Q4 		$389K Buy
25,169
+8,913
+55% +$105K ﹤0.01% 2504
2025
Q3 		$141K Hold
16,256
– – ﹤0.01% 2865
2025
Q2 		$163K Buy
+16,256
New +$553K ﹤0.01% 2779
2023
Q1 		– Sell
-378
Closed -$387K – 2927
2022
Q4 		$387K Buy
+378
New +$274K ﹤0.01% 2264

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates's JBIO Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Jade Biosciences (JBIO) stake by 10% in Q1 2026, selling an estimated $37.5K and leaving 22,578 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #2659.

T. Rowe Price Associates first reported a position in JBIO in Q4 2022 and has held it in 5 quarters since. The position peaked at $389K in Q4 2025. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • T. Rowe Price Associates held 22,578 shares of Jade Biosciences worth $318K as of Q1 2026.
  • T. Rowe Price Associates sold 2,591 Jade Biosciences shares in Q1 2026, an estimated $37.5K.
  • Jade Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2659 holding.
  • T. Rowe Price Associates first reported a position in Jade Biosciences in Q4 2022 and has held it in 5 quarters since.
  • T. Rowe Price Associates's Jade Biosciences position peaked at $389K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.